{"transactions":[{"id":700000,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-31T20:05:14.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":false,"shares":21854,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1.26,"expiration_date":"2026-08-31","underlying":"Common Stock","underlying_shares":21854},"source":{"system":"sec-edgar","filing":"0001193125-26-328467","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526328467/ownership.xml","form_type":"4"}},{"id":699999,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-31T20:05:14.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":true,"shares":21854,"price":1.26,"value":27536.04,"ownership":{"direct":true},"balance_after":21854,"source":{"system":"sec-edgar","filing":"0001193125-26-328467","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526328467/ownership.xml","form_type":"4"}},{"id":722803,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-30T20:05:10.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":155000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date."}],"balance_after":155000,"derivative":{"exercise_price":1.91,"expiration_date":"2036-06-26","underlying":"Common Stock","underlying_shares":155000},"source":{"system":"sec-edgar","filing":"0001193125-26-290477","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526290477/ownership.xml","form_type":"4"}},{"id":1095286,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T23:40:36.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":108176,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date."}],"balance_after":108176,"derivative":{"exercise_price":1.95,"expiration_date":"2032-06-30","underlying":"Common Stock","underlying_shares":108176},"source":{"system":"sec-edgar","filing":"0000950170-25-093428","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025093428/ownership.xml","form_type":"4"}},{"id":1260146,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-20T01:06:52.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Reporting Person's original Form 4, which was filed with the Securities and Exchange Commission on January 22, 2025 inadvertently reported Molino Ventures, LLC as the beneficial owner. This Form 4 amendment is being filed to report the correct beneficial owner as the Reporting Person. Except as noted in this amended Form 4, all other information disclosed in the Reporting Person's original Form 4 was accurately reported."}],"balance_after":30000,"derivative":{"exercise_price":1.26,"expiration_date":"2031-07-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-25-023572","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025023572/ownership.xml","form_type":"4/A","original_submission_date":"2025-01-22"}},{"id":1260145,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-20T01:06:52.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":6667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Reporting Person's original Form 4, which was filed with the Securities and Exchange Commission on January 22, 2025 inadvertently reported Molino Ventures, LLC as the beneficial owner. This Form 4 amendment is being filed to report the correct beneficial owner as the Reporting Person. Except as noted in this amended Form 4, all other information disclosed in the Reporting Person's original Form 4 was accurately reported."}],"balance_after":6667,"derivative":{"exercise_price":1.26,"expiration_date":"2030-06-30","underlying":"Common Stock","underlying_shares":6667},"source":{"system":"sec-edgar","filing":"0000950170-25-023572","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025023572/ownership.xml","form_type":"4/A","original_submission_date":"2025-01-22"}},{"id":1260144,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-20T01:06:52.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":6667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Reporting Person's original Form 4, which was filed with the Securities and Exchange Commission on January 22, 2025 inadvertently reported Molino Ventures, LLC as the beneficial owner. This Form 4 amendment is being filed to report the correct beneficial owner as the Reporting Person. Except as noted in this amended Form 4, all other information disclosed in the Reporting Person's original Form 4 was accurately reported."}],"balance_after":6667,"derivative":{"exercise_price":1.26,"expiration_date":"2029-06-24","underlying":"Common Stock","underlying_shares":6667},"source":{"system":"sec-edgar","filing":"0000950170-25-023572","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025023572/ownership.xml","form_type":"4/A","original_submission_date":"2025-01-22"}},{"id":1260143,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-20T01:06:52.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":3780,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Reporting Person's original Form 4, which was filed with the Securities and Exchange Commission on January 22, 2025 inadvertently reported Molino Ventures, LLC as the beneficial owner. This Form 4 amendment is being filed to report the correct beneficial owner as the Reporting Person. Except as noted in this amended Form 4, all other information disclosed in the Reporting Person's original Form 4 was accurately reported."}],"balance_after":3780,"derivative":{"exercise_price":1.26,"expiration_date":"2028-06-25","underlying":"Common Stock","underlying_shares":3780},"source":{"system":"sec-edgar","filing":"0000950170-25-023572","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025023572/ownership.xml","form_type":"4/A","original_submission_date":"2025-01-22"}},{"id":1260142,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-20T01:06:52.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":21854,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Reporting Person's original Form 4, which was filed with the Securities and Exchange Commission on January 22, 2025 inadvertently reported Molino Ventures, LLC as the beneficial owner. This Form 4 amendment is being filed to report the correct beneficial owner as the Reporting Person. Except as noted in this amended Form 4, all other information disclosed in the Reporting Person's original Form 4 was accurately reported."}],"balance_after":21854,"derivative":{"exercise_price":1.26,"expiration_date":"2026-08-31","underlying":"Common Stock","underlying_shares":21854},"source":{"system":"sec-edgar","filing":"0000950170-25-023572","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025023572/ownership.xml","form_type":"4/A","original_submission_date":"2025-01-22"}},{"id":1260149,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-20T01:00:55.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":39620,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vested and became exercisable on February 14, 2025."}],"balance_after":39620,"derivative":{"exercise_price":2.35,"expiration_date":"2035-02-14","underlying":"Common Stock","underlying_shares":39620},"source":{"system":"sec-edgar","filing":"0000950170-25-023565","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025023565/ownership.xml","form_type":"4"}},{"id":1297725,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Molino Ventures, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":30000,"derivative":{"exercise_price":1.26,"expiration_date":"2031-07-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-25-007744","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007744/ownership.xml","form_type":"4"}},{"id":1297724,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Molino Ventures, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":1.54,"expiration_date":"2031-07-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-25-007744","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007744/ownership.xml","form_type":"4"}},{"id":1297723,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":6667,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Molino Ventures, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":6667,"derivative":{"exercise_price":1.26,"expiration_date":"2030-06-30","underlying":"Common Stock","underlying_shares":6667},"source":{"system":"sec-edgar","filing":"0000950170-25-007744","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007744/ownership.xml","form_type":"4"}},{"id":1297722,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6667,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Molino Ventures, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":3.61,"expiration_date":"2030-06-30","underlying":"Common Stock","underlying_shares":6667},"source":{"system":"sec-edgar","filing":"0000950170-25-007744","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007744/ownership.xml","form_type":"4"}},{"id":1297721,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":6667,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Molino Ventures, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."}],"balance_after":6667,"derivative":{"exercise_price":1.26,"expiration_date":"2029-06-24","underlying":"Common Stock","underlying_shares":6667},"source":{"system":"sec-edgar","filing":"0000950170-25-007744","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007744/ownership.xml","form_type":"4"}},{"id":1297720,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6667,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Molino Ventures, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."}],"balance_after":0,"derivative":{"exercise_price":4.86,"expiration_date":"2029-06-24","underlying":"Common Stock","underlying_shares":6667},"source":{"system":"sec-edgar","filing":"0000950170-25-007744","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007744/ownership.xml","form_type":"4"}},{"id":1297719,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":3780,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Molino Ventures, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."}],"balance_after":3780,"derivative":{"exercise_price":1.26,"expiration_date":"2028-06-25","underlying":"Common Stock","underlying_shares":3780},"source":{"system":"sec-edgar","filing":"0000950170-25-007744","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007744/ownership.xml","form_type":"4"}},{"id":1297718,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3780,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Molino Ventures, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."}],"balance_after":0,"derivative":{"exercise_price":17.52,"expiration_date":"2028-06-25","underlying":"Common Stock","underlying_shares":3780},"source":{"system":"sec-edgar","filing":"0000950170-25-007744","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007744/ownership.xml","form_type":"4"}},{"id":1297717,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":1138,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."}],"balance_after":1138,"derivative":{"exercise_price":1.26,"expiration_date":"2027-12-22","underlying":"Common Stock","underlying_shares":1138},"source":{"system":"sec-edgar","filing":"0000950170-25-007744","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007744/ownership.xml","form_type":"4"}},{"id":1297716,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1138,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The acquisition of the reported option was reported in a Form 4 filed on December 29, 2020, which mistakenly reported the expiration date as December 22, 2030."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."}],"balance_after":0,"derivative":{"exercise_price":60,"expiration_date":"2027-12-22","underlying":"Common Stock","underlying_shares":1138},"source":{"system":"sec-edgar","filing":"0000950170-25-007744","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007744/ownership.xml","form_type":"4"}},{"id":1297715,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":21854,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Molino Ventures, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."}],"balance_after":21854,"derivative":{"exercise_price":1.26,"expiration_date":"2026-08-31","underlying":"Common Stock","underlying_shares":21854},"source":{"system":"sec-edgar","filing":"0000950170-25-007744","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007744/ownership.xml","form_type":"4"}},{"id":1297714,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-22T21:05:06.000Z","date":"2025-01-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":21854,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Molino Ventures, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect an option repricing (the \"Repricing\") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023."}],"balance_after":0,"derivative":{"exercise_price":33.43,"expiration_date":"2026-08-31","underlying":"Common Stock","underlying_shares":21854},"source":{"system":"sec-edgar","filing":"0000950170-25-007744","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025007744/ownership.xml","form_type":"4"}},{"id":1308137,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-07T23:38:02.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":316647,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series B-1 Warrants in an amount proportional to the actual number of Series B-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof."}],"balance_after":316647,"derivative":{"exercise_price":1.58,"expiration_date":"2035-01-03","underlying":"Common Stock","underlying_shares":316647},"source":{"system":"sec-edgar","filing":"0000950170-25-003123","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025003123/ownership.xml","form_type":"4"}},{"id":1308136,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-07T23:38:02.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":172191,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series A-1 Warrants in an amount proportional to the actual number of Series A-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof."}],"balance_after":172191,"derivative":{"exercise_price":1.45,"expiration_date":"2035-01-03","underlying":"Common Stock","underlying_shares":172191},"source":{"system":"sec-edgar","filing":"0000950170-25-003123","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025003123/ownership.xml","form_type":"4"}},{"id":1308135,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-07T23:38:02.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":344452,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vested and became exercisable on October 9, 2024."}],"balance_after":344452,"derivative":{"exercise_price":1.26,"expiration_date":"2035-01-03","underlying":"Common Stock","underlying_shares":344452},"source":{"system":"sec-edgar","filing":"0000950170-25-003123","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025003123/ownership.xml","form_type":"4"}},{"id":1451852,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-18T21:20:28.000Z","date":"2024-07-16","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Molino Ventures, LLC"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest on the earlier of July 16, 2025 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date."}],"balance_after":30000,"derivative":{"exercise_price":1.54,"expiration_date":"2031-07-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-084656","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017024084656/ownership.xml","form_type":"4"}},{"id":1836442,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right  to buy)","published_at":"2023-07-06T01:18:11.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":6667,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By  Molino  Ventures,  LLC"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest on the earlier of June 30, 2024 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date."}],"balance_after":6667,"derivative":{"exercise_price":3.61,"expiration_date":"2030-06-30","underlying":"Common Stock","underlying_shares":6667},"source":{"system":"sec-edgar","filing":"0000950170-23-031856","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017023031856/ownership.xml","form_type":"4"}},{"id":2220220,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-29T01:00:22.000Z","date":"2022-06-24","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Molino Ventures, LLC"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This entire stock option grant will vest 100% in a single tranche on the earlier of June 24, 2023 or the day prior to the next annual meeting of stockholders."}],"balance_after":40000,"derivative":{"exercise_price":0.81,"expiration_date":"2029-06-24","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-22-039708","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000120919122039708/doc4.xml","form_type":"4"}},{"id":2651888,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-29T23:09:39.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":22677,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Molino Ventures, LLC"},"balance_after":22677,"derivative":{"exercise_price":2.92,"exercise_date":"2022-06-25","expiration_date":"2028-06-25","underlying":"Common Stock","underlying_shares":22677},"source":{"system":"sec-edgar","filing":"0001104659-21-086987","document":"tm2120992d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000110465921086987/tm2120992d1_4.xml","form_type":"4"}},{"id":2930281,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":27505,"kind":"person","name":"BERMAN DENNIS N","position":1,"cik":"0001273858","reported_name":"BERMAN DENNIS N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-12-30T02:53:34.000Z","date":"2020-12-22","kind":"grant","acquired":true,"shares":6825,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6825,"derivative":{"exercise_price":10,"exercise_date":"2021-12-22","expiration_date":"2030-12-22","underlying":"Common Stock","underlying_shares":6825},"source":{"system":"sec-edgar","filing":"0001104659-20-140312","document":"tm2039455d6_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000110465920140312/tm2039455d6_form4.xml","form_type":"4"}}]}